Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,301 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,832 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01616238 | A Study for Older Adults With Acute Lymphoblastic Leukaemia(UKALL60+) | completed | Phase 2 | 126 | University College, LondonOTHER | 2 | Aug 16, 2023 | clinicaltrials |
| NCT03882203 | CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia | completed | Phase 2 | 18 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT03010358 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 24 | Alexey Danilov, MDOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00030875 | Bortezomib in Treating Patients With Mantle Cell Lymphoma | completed | Phase 2 | 30 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00377052 | Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 29 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01145989 | A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01627054 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 7 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01652144 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03215524 | A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide(DCDP) | completed | Phase 2 | 120 | Canadian Myeloma Research GroupOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03702231 | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) | completed | Phase 2 | 116 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT01267812 | Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation | completed | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT01772420 | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia | completed | Phase 2 | 52 | Albert Einstein College of MedicineOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | completed | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2023 | clinicaltrials |
| NCT03435848 | Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy(ELPIS) | completed | Phase 2 | 66 | BioSight Ltd.INDUSTRY | 2 | Jul 27, 2023 | clinicaltrials |
| NCT03959358 | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01399372 | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | completed | Phase 2 | 91 | Radiation Therapy Oncology GroupNETWORK | 2 | Jul 20, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT03192202 | AFM13 in Relapsed/Refractory Cutaneous Lymphomas | completed | Phase 1 / Phase 2 | 18 | Ahmed SawasOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03050216 | QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML | completed | Phase 2 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01203020 | Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | completed | Phase 2 | 22 | West Virginia UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04954326 | A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)(ALL) | completed | Phase 2 | 89 | Institut de Recherches Internationales ServierOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02185820 | Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)(CPD) | completed | Phase 1 / Phase 2 | 57 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02204241 | Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients(CCD) | completed | Phase 1 / Phase 2 | 36 | European Myeloma Network B.V.NETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00074282 | Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL | completed | Phase 2 | 102 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00274924 | Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 100 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01160107 | Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients(RP_MPR) | completed | Phase 2 | 46 | Fondazione EMN Italy OnlusOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01166113 | Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide(PCP) | completed | Phase 1 / Phase 2 | 67 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01216683 | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | completed | Phase 2 | 289 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02226965 | PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) | completed | Phase 2 | 45 | Sierra Oncology LLC - a GSK companyINDUSTRY | 2 | Jun 29, 2023 | clinicaltrials |
| NCT00045305 | Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes | completed | Phase 2 | 17 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 11 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT04562792 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 1 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01754857 | Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04687098 | Risk-adapted Therapy for Primary Acute Myeloid Leukemia | completed | Phase 2 | 1,034 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2023 | clinicaltrials |
| NCT00003388 | Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003808 | Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00005962 | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00006390 | Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT01733238 | Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 13 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02030834 | Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | completed | Phase 2 | 63 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 16, 2023source: clinicaltrials